CINECA IRIS Institutional Research Information System

FONTANINI, GABRIELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.878
AS - Asia 13.633
EU - Europa 9.161
SA - Sud America 2.122
AF - Africa 572
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 10
Totale 52.399
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.154
SG - Singapore 4.464
CN - Cina 3.556
HK - Hong Kong 2.344
IT - Italia 2.237
BR - Brasile 1.784
DE - Germania 1.539
SE - Svezia 1.217
VN - Vietnam 1.121
BG - Bulgaria 899
GB - Regno Unito 691
CA - Canada 572
TR - Turchia 570
FR - Francia 542
UA - Ucraina 466
FI - Finlandia 455
RU - Federazione Russa 445
KR - Corea 336
IN - India 272
CI - Costa d'Avorio 194
JP - Giappone 191
BD - Bangladesh 160
AT - Austria 159
CH - Svizzera 136
IQ - Iraq 117
AR - Argentina 110
SN - Senegal 83
MX - Messico 78
ID - Indonesia 75
ZA - Sudafrica 73
NL - Olanda 68
PL - Polonia 62
BE - Belgio 61
UZ - Uzbekistan 61
PK - Pakistan 52
SA - Arabia Saudita 51
CO - Colombia 49
EC - Ecuador 48
NG - Nigeria 42
MA - Marocco 41
VE - Venezuela 40
ES - Italia 39
JO - Giordania 30
KE - Kenya 28
PH - Filippine 28
AE - Emirati Arabi Uniti 24
EG - Egitto 24
PY - Paraguay 23
AU - Australia 22
IL - Israele 22
CL - Cile 20
AL - Albania 19
AZ - Azerbaigian 19
DZ - Algeria 18
TN - Tunisia 18
LT - Lituania 17
UY - Uruguay 17
CZ - Repubblica Ceca 16
IE - Irlanda 16
PE - Perù 16
NP - Nepal 15
MY - Malesia 13
CR - Costa Rica 12
RO - Romania 12
KZ - Kazakistan 11
BJ - Benin 10
JM - Giamaica 10
PT - Portogallo 10
TH - Thailandia 10
BO - Bolivia 9
DK - Danimarca 9
EU - Europa 9
OM - Oman 9
TT - Trinidad e Tobago 9
ET - Etiopia 8
NI - Nicaragua 8
AM - Armenia 7
BB - Barbados 7
GE - Georgia 7
LB - Libano 7
PS - Palestinian Territory 7
SY - Repubblica araba siriana 7
TW - Taiwan 7
GR - Grecia 6
HU - Ungheria 6
IR - Iran 6
PA - Panama 6
AO - Angola 5
BH - Bahrain 5
DO - Repubblica Dominicana 5
HN - Honduras 5
MD - Moldavia 5
CG - Congo 4
EE - Estonia 4
KG - Kirghizistan 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
LU - Lussemburgo 4
NO - Norvegia 4
QA - Qatar 4
Totale 52.325
Salva come PNG Salva come JPEG
Città #
Ashburn 2.805
Singapore 2.476
Hong Kong 2.316
Fairfield 2.258
Woodbridge 2.132
Chandler 1.741
Houston 1.601
Dallas 1.563
Ann Arbor 1.415
Santa Clara 1.283
San Jose 1.255
Seattle 955
Sofia 897
Wilmington 852
Cambridge 798
Beijing 771
Shanghai 745
New York 580
Jacksonville 474
Ottawa 464
Boardman 453
Milan 402
Hefei 393
Princeton 391
Los Angeles 372
Lawrence 364
Izmir 328
Seoul 326
Medford 325
Lauterbourg 324
Nanjing 293
Des Moines 259
Ho Chi Minh City 254
Serra 250
Pisa 228
Abidjan 194
Hanoi 190
Florence 185
Council Bluffs 172
Istanbul 166
Tokyo 166
Dong Ket 163
São Paulo 159
Dearborn 155
Buffalo 145
Columbus 143
The Dalles 143
Boulder 133
Redondo Beach 128
Bern 124
Vienna 123
Frankfurt am Main 120
San Diego 115
Munich 113
London 111
Nanchang 100
Helsinki 98
Falls Church 89
Dakar 83
Kunming 83
Bremen 82
Ogden 79
Jüchen 70
Lancaster 68
Rio de Janeiro 68
Chicago 66
Brussels 55
Tashkent 54
Pune 53
Turku 52
Baghdad 50
Düsseldorf 50
Hebei 50
Shenyang 50
Warsaw 49
Redwood City 47
Da Nang 43
Belo Horizonte 42
Nuremberg 42
Changsha 41
Phoenix 40
Rome 40
Lagos 39
Jiaxing 38
Fuzhou 36
Guangzhou 34
Orem 34
Toronto 34
Montreal 33
Washington 33
Jakarta 32
San Francisco 31
Seacroft 30
Tianjin 30
Chennai 29
Johannesburg 29
Amman 28
Dhaka 27
Porto Alegre 27
Amsterdam 26
Totale 37.505
Salva come PNG Salva come JPEG
Nome #
null 346
La densità microvascolare (DMV) come marker prognostico e predittivo nelle neoplasie maligne dell'albero bronchiale in fase avanzata. 298
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 295
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 267
Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience 251
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 246
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines 244
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 239
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 226
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 226
Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance 220
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 218
Percutaneous radiofrequency ablation (pRTA) of pulmonary tumors 214
Evaluation of telomerase in the development and progression of colon cancer. Int J Mol Med. 2002 Nov;10(5):589-92 213
An atypical presentation of sporadic adult-onset centronuclear myopathy 212
EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center 212
210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia 210
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 208
Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma. 206
Reply to P.M. Foye ( Letter ) 200
Nodal upstaging evaluation in NSCLC patients treated by robotic lobectomy 200
Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features 198
Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction 194
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 193
Second primary lung cancer and relapse: treatment and follow-up. 192
Screen-detected multiple primary lung cancers in the ITALUNG trial 192
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 192
TERMOABLAZIONE DI NEOPLASIE POLMONARI MALIGNE: QUALI PROSPETTIVE 191
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial 191
Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology? 191
Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report 191
Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas 191
A high vascular count and overexpression of Vascular Endothelial Growth Factor (VEGF) are associated with unfavorable prognosis in operated Small Cell Carcinoma (SCLC) 190
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments 190
Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism 190
miR-19a and miR-20a and tissue factor expression in activated human peripheral blood mononuclear cells 189
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts 188
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 188
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma 188
Mutations of Fas (APO-1/CD95) and p53 genes in nonmelanoma skin cancer 188
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 188
Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: a positive prognostic factor for survival? 187
FR-MLV INFECTION INDUCES ERYTHROLEUKEMIA INSTEAD OF LYMPHOID LEUKEMIA IN MICE GIVEN PITUITARY GRAFTS 186
Differential microRNA expression profiles between young and old lung adenocarcinoma patients. 186
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A 183
Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study 183
Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. 183
Alterations of Fas (APO-1/CD95) gene and its relationship with p53 in non small cell lung cancer 180
Applications of tissue microarray technology in immunohistochemistry: a study on c-kit expression in small cell lung cancer 180
CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma 180
Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma 180
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib 179
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 179
2ND PRIMARY LUNG-CANCER AND RELAPSE - TREATMENT AND FOLLOW-UP 178
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 178
Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression 177
A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations. 175
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer 173
THE EXPRESSION OF PROLIFERATING CELL NUCLEAR ANTIGEN IN PARAFFIN SECTIONS OF PERIPHERAL, NODE-NEGATIVE NON-SMALL-CELL LUNG-CANCER 172
Neoangiogenesis as prognostic indicator of survival in lung cancer. 171
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 171
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC). 171
KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung 171
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 171
Accumulation of gene protein product P53 correlates with high microvessel count in non small cell lung carcinomas 170
ANGIOGENIC POTENTIAL IN-VIVO BY KAPOSIS-SARCOMA CELL-FREE SUPERNATANTS AND HIV-1 TAT PRODUCT - INHIBITION OF KS-LIKE LESIONS BY TISSUE INHIBITOR OF METALLOPROTEINASE-2 170
Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice 170
Laparoscopic and thoracoscopic simultaneous resection of synchronous rectal and lung cancer 170
Evaluation of telomerase in non-melanoma skin cancer 170
Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients 170
Expression Profiling of LKB1 Pathway in Young and Old Lung Adenocarcinoma Patients. 170
LAPAROSCOPIC AND THORACHOSCOPIC SIMULATANEOUS RESECTION OF SYNCHRONOUS RECTAL AND LUNG CANCER 169
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. 169
A preliminary study on radiofrequency thermal ablation of lung tumors 168
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: A literature review 168
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 168
The multimodality treatment of thymic carcinoma 167
Neoangiogenesis: A putative marker of malignancy in non-small-cell lung cancer (NSCLC) development 167
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma 167
Potentiation of the malignant phenotype of the undifferentiated aro thyroid cell line by insertion of the bcl-2 gene 166
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 166
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 166
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 164
Immunohistochemical and molecular study of radiation-induced multiple meningiomas with pleural and pulmonary metastasis 164
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients 164
VALUTAZIONE DELL'ATTIVITA' TELOMERASICA E DELL'ESPRESSIONE DI hTERT mRNA IN ADENOCARCINOMA DEL COLON 163
Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients 163
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 162
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 162
Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer 162
Lung metastasectomy after colorectal cancer: prognostic impact of resection margin on long term survival, a retrospective cohort study. 162
BLOOD-VESSEL INVASION BY TUMOR-CELLS PREDICTS RECURRENCE IN COMPLETELY RESECTED T1-N0-M0 NON-SMALL-CELL LUNG-CANCER 161
Clear cell adenocarcinoma of the base of the tongue: a case report and review of the literature 161
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 161
Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations 161
Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction 160
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 160
N2 lung cancer is not all the same: an analysis of different prognostic groups 159
Markers of cell proliferation as prognostic factors in differentiated thyroid cancer. 158
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 158
Totale 18.796
Salva come PNG Salva come JPEG
Categoria #
all - tutte 152.223
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 152.223
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021846 0 0 0 0 0 0 0 0 0 215 164 467
2021/20224.005 48 289 112 219 757 636 105 193 200 170 155 1.121
2022/20234.706 552 541 296 479 560 654 25 380 846 19 324 30
2023/20242.986 315 317 394 145 432 590 84 84 80 45 151 349
2024/202511.825 84 448 86 649 1.095 1.169 943 669 1.214 1.561 1.347 2.560
2025/202611.738 825 1.557 1.857 916 1.177 1.144 2.043 625 601 993 0 0
Totale 53.036